AA suppresses oxidative stress to inhibit the nuclear translocation of Nrf2, and treatment with AA sensitizes cells to imatinib in imatinib-resistant chronic myelogenous leukemia KCL22/SR cells 102. Here, NFE2L2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.